On Tuesday, Quest Diagnostics, Inc (NYSE: DGX) opened higher 1.86% from the last session, before settling in for the closing price of $152.65. Price fluctuations for DGX have ranged from $123.04 to $165.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 4.86% annually for the last half of the decade. Company’s average yearly earnings per share was noted 2.17% at the time writing. With a float of $111.06 million, this company’s outstanding shares have now reached $112.00 million.
In an organization with 48000 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 32.31%, operating margin of 13.94%, and the pretax margin is 11.67%.
Quest Diagnostics, Inc (DGX) Insider Updates
A key investor’s attitude towards the stock of the Diagnostics & Research industry is another important factor to consider. The insider ownership of Quest Diagnostics, Inc is 0.50%, while institutional ownership is 89.56%. The most recent insider transaction that took place on Nov 29 ’24, was worth 5,731,302. In this transaction SVP & General Counsel of this company sold 35,146 shares at a rate of $163.07, taking the stock ownership to the 38,478 shares. Before that another transaction happened on Nov 27 ’24, when Company’s EVP, Regional Businesses sold 33,103 for $162.99, making the entire transaction worth $5,395,484. This insider now owns 68,412 shares in total.
Quest Diagnostics, Inc (DGX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 2.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.50% during the next five years compared to 7.36% growth over the previous five years of trading.
Quest Diagnostics, Inc (NYSE: DGX) Trading Performance Indicators
Check out the current performance indicators for Quest Diagnostics, Inc (DGX). In the past quarter, the stock posted a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.82. Likewise, its price to free cash flow for the trailing twelve months is 16.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.45, a number that is poised to hit 2.19 in the next quarter and is forecasted to reach 9.73 in one year’s time.
Technical Analysis of Quest Diagnostics, Inc (DGX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.9 million. That was inferior than the volume of 0.91 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 15.60%. Additionally, its Average True Range was 2.95.
During the past 100 days, Quest Diagnostics, Inc’s (DGX) raw stochastic average was set at 60.06%, which indicates a significant increase from 28.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 14.80% in the past 14 days, which was lower than the 19.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $156.52, while its 200-day Moving Average is $145.43. However, in the short run, Quest Diagnostics, Inc’s stock first resistance to watch stands at $157.23. Second resistance stands at $158.98. The third major resistance level sits at $161.42. If the price goes on to break the first support level at $153.05, it is likely to go to the next support level at $150.61. Assuming the price breaks the second support level, the third support level stands at $148.86.
Quest Diagnostics, Inc (NYSE: DGX) Key Stats
There are currently 111,615K shares outstanding in the company with a market cap of 17.36 billion. Presently, the company’s annual sales total 9,252 M according to its annual income of 854,000 K. Last quarter, the company’s sales amounted to 2,488 M and its income totaled 226,000 K.
